Παρακολούθηση
Kaushik Thakkar
Kaushik Thakkar
Senior Scientist, Janssen Pharmaceutical Companies of Johnson & Johnson
Η διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα its.jnj.com
Τίτλος
Παρατίθεται από
Παρατίθεται από
Έτος
Biological synthesis of metallic nanoparticles
KN Thakkar, SS Mhatre, RY Parikh
Nanomedicine: nanotechnology, biology and medicine 6 (2), 257-262, 2010
30102010
The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor
Y Xiao, KN Thakkar, H Zhao, J Broughton, Y Li, JA Seoane, AN Diep, ...
Proceedings of the National Academy of Sciences 117 (35), 21441-21449, 2020
892020
The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling
EJ Moon, SS Mello, CG Li, JT Chi, K Thakkar, JG Kirkland, EL Lagory, ...
Nature communications 12 (1), 4308, 2021
792021
TRIM24 links glucose metabolism with transformation of human mammary epithelial cells
TN Pathiraja, KN Thakkar, S Jiang, S Stratton, Z Liu, M Gagea, X Shi, ...
Oncogene 34 (22), 2836-2845, 2015
612015
Generation of stable expression mammalian cell lines using lentivirus
N Tandon, KN Thakkar, EL LaGory, Y Liu, AJ Giaccia
Bio-protocol 8 (21), e3073-e3073, 2018
562018
Neutralization of PD-L2 is essential for overcoming immune checkpoint blockade resistance in ovarian cancer
YR Miao, KN Thakkar, J Qian, MS Kariolis, W Huang, S Nandagopal, ...
Clinical cancer research 27 (15), 4435-4448, 2021
542021
Regulation of gene expression in human cancers by TRIM24
S Appikonda, KN Thakkar, MC Barton
Drug Discovery Today: Technologies 19, 57-63, 2016
522016
Cross-talk between chromatin acetylation and SUMOylation of tripartite motif–containing protein 24 (TRIM24) impacts cell adhesion
S Appikonda, KN Thakkar, PK Shah, SYR Dent, JN Andersen, MC Barton
Journal of Biological Chemistry 293 (19), 7476-7485, 2018
352018
Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination–deficient cancer models
M Mehibel, Y Xu, CG Li, EJ Moon, KN Thakkar, AN Diep, RK Kim, ...
The Journal of clinical investigation 131 (11), 2021
242021
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma
YR Miao, K Thakkar, C Cenik, D Jiang, K Mizuno, C Jia, CG Li, H Zhao, ...
Journal of Experimental Medicine 219 (9), e20220214, 2022
102022
Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer
AJG Yu Miao, Kaushik N. Thakkar, Jin Qian, Mihalis S. Kariolis, Huang Wei ...
bioRxiV, 2020
32020
Tissue-specific metabolism and TRIM24
KN Thakkar, SA Stratton, MC Barton
Aging (Albany NY) 7 (10), 736, 2015
32015
Modulating the tumor microenvironment to enhance efficacy of PARP inhibitors.
M Mehibel, J Xu, A Diep, K Thakkar, CG Li, Y Xiao, E Rankin, A Giaccia
Journal of Clinical Oncology 37 (15_suppl), e14715-e14715, 2019
22019
Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade
YR Miao, KN Thakkar, J Qian, MS Kariolis, W Huang, N Saravanan, Y Xu
Oncol 152 (2), 243-250, 2019
12019
sBCMA Variants and FC Fusion Proteins Thereof
AJ Giaccia, Y Miao, K Thakkar, K Mizuno
US Patent App. 18/041,527, 2024
2024
sPD-1 VARIANT–FC FUSION PROTEINS
AJ Giaccia, TA Aguilera, MS Kariolis, Y Miao, K Thakkar, XE Zhang
US Patent App. 17/962,983, 2023
2023
SPD-1 variant# FC fusion proteins
AJ Giaccia, TA Aguilera, MS Kariolis, Y Miao, K Thakkar, XE Zhang
US Patent 11,498,955, 2022
2022
Abstract IA-003: Oxygen dependent resistance to PARP inhibitors
M Mehibel, J Xu, G Li, J Moon, K Thakkar, A Diep, R Kim, J Bloomstein, ...
Clinical Cancer Research 27 (8_Supplement), IA-003-IA-003, 2021
2021
Reading histone modifications, an oncoprotein is modified in return
News-Article
https://bit.ly/2KKaJdM https://bit.ly/2GGEOZb https://bit.ly/2KOVoc3 https …, 2018
2018
Trim24 Orchestrates Metabolic Reprogramming And Emt In Breast Cancer
K Thakkar
2016
Δεν είναι δυνατή η εκτέλεση της ενέργειας από το σύστημα αυτή τη στιγμή. Προσπαθήστε ξανά αργότερα.
Άρθρα 1–20